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Abstract
Recent improvements in the understanding of brain tumor biology have opened the door to
a number of rational therapeutic strategies targeting distinct oncogenic pathways. The
successful translation of such “designer drugs” to clinical application depends heavily on
effective and expeditious screening methods in relevant disease models. By recapitulating
boththeunderlyinggeneticsandthecharacteristictumor-stromamicroenvironmentofbrain
cancer, genetically engineered mouse models (GEMMs) may offer distinct advantages over
cell culture and xenograft systems in the preclinical testing of promising therapies. This
review focuses on recently developed GEMMs for both glioma and medulloblastoma, and
discusses their potential use in preclinical trials. Examples showcasing the use of GEMMs
in the testing of molecularly targeted therapeutics are given, and relevant topics, such as
stem cell biology, in vivo imaging technology and radiotherapy, are also addressed.
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INTRODUCTION
The treatment challenges posed by primary brain tumors are mani-
fold and are enhanced by unique features of the intracranial envi-
ronment. For instance, the well-established ability of many brain
tumors to widely diffuse into surrounding normal parenchyma
frequently precludes complete surgical resection. Additionally,
pharmaceutical intervention can be hampered by the blood–brain
barrier and the inability to effectively deliver drugs into a given
tumor mass. The development of effective therapeutics is further
complicated by the genetic heterogeneity exhibited not only
between tumors of the same subtype, but also within individual
tumors. Recent work has highlighted such molecular complexity
in both glioma and medulloblastoma, the most common primary
brain tumors in adult and pediatric populations, respectively (20,
67). Nevertheless, the mainstays of nonsurgical treatment for both
of these conditions remain strikingly similar, consisting of some
combination of radiation and cytotoxic chemotherapy (67, 86). For
glioblastoma multiforme (GBM), the most malignant variant of
glioma, the alkylating agent temozolomide in combination with
radiotherapy has recently resulted in a marginal increase in median
survival to approximately 15 months (74), and now represents the
standard of care for a variety of glioma subtypes. Radiation and
chemotherapy have shown greater efﬁcacy in the treatment of
medulloblastoma, where 5-year survival rates are now as high as
70%–80% (21). However, the long-term side effects of these con-
ventional modalities, especially when applied to the developing
brain, remain problematic.
The shortcomings of the current standards of care highlighted
above underscore the pressing need for rationally conceived
therapies targeted to the speciﬁc molecular pathways deregulated
in primary brain tumors. Recent advances in tumor biology have
revealed no shortage of potential targets for therapeutic interven-
tion, and new compounds are being developed continually. The
obvious next challenge has now become the efﬁcient screening of
promising therapies, either alone or in combination, in biologically
relevantsystems.Inclinicaloncology,mostdrugsfailinlatedevel-
opment after enormous ﬁnancial investments, typically due to
a lack of efﬁcacy in human subjects. This places a premium on
quality preclinical testing to (i) select appropriate molecular
targets; (ii) determine the effectiveness of drugs directed against
thosetargetsandtheidealgeneticandcellularcontextfortheiruse;
(iii) evaluate the toxicity of selected drugs; and (iv) identify rel-
evant biomarkers demonstrating drug efﬁcacy and speciﬁcity to
assist in subsequent clinical trials (71).
Cancer modeling for preclinical testing relies on both in vitro
andinvivosystems.Tumor-derivedcelllinesplayanimportantrole
in this process and are often the initial reagents employed for drug
screening because of their ready availability and ease of use.
However, the inability of cell culture experiments to fully
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and the complexity of tumor-stroma interactions places obvious
limitations on the extent to which data derived from such studies
can be interpreted. Xenograft analysis represents the most fre-
quently used in vivo modeling system for the testing of anticancer
therapeutics, primarily because of low cost and ease of implemen-
tation. To form a xenograft, primary tumor cells or cell lines are
injected either subcutaneously or orthotopically (into the native
tumor site) into immunocompetent or immunonaive mice. The
shortcomings of this approach as a high-ﬁdelity cancer model
center both on the inability of extensively passaged cell lines to
accurately represent the diverse molecular and cellular characteris-
tics of naïve tumors and the failure of foreign transplantation sites
to fully embody the native stromal microenvironment (5, 16, 71).
While these problems can be addressed somewhat by the use of
minimally passaged tumor cells and exclusively orthotopic trans-
plantation, issues concerning the perturbed stromal setting of
immunodeﬁcient murine hosts remain. Therefore, it seems hardly
surprising that xenograft testing for cancer drug development has
demonstrated limited predictive value (71).
The recent development of several distinct murine models of
medulloblastoma and glioma (both astrocytic and oligodendroglial
variants) has provided more physiologically relevant in vivo
systems for the evaluation of anticancer therapies. While geneti-
cally engineered mouse models (GEMMs) also have their limita-
tions (see below), they more accurately recapitulate the casual
genetic events and subsequent molecular evolution of brain tumors
as they form in situ. Furthermore, some GEMMs give rise to
tumor-stroma interactions resembling those found in native
tumors, and appear to harbor cellular subpopulations like cancer
stem cells (CSCs) thought to be of central importance to the devel-
opment, maintenance and drug resistance of brain cancer. This
review will summarize the current state of genetically engineered
mouse modeling for both glioma and medulloblastoma in the
contextofdevelopingmoreeffectivepreclinicalscreeningmethods
for novel cancer therapeutics.
GEMMS AS MODELS FOR PRECLINICAL
TESTING
As highlighted elsewhere in this issue, GEMMs provide powerful
systems with which to address many of the pressing issues in
modern cancer biology, including but not limited to the molecular
mechanisms and cellular origins of neoplastic processes, along
with the importance of the tumor microenvironment. Nevertheless,
not all GEMMs are suitable for preclinical testing for any one of a
number of factors. The ideal mouse model for drug development
would (i) faithfully recapitulate the genetics and molecular charac-
teristics of the human tumor in question; (ii) posses a short tumor
latency and high penetrance; (iii) be relatively simple to generate
and easy to use; and (iv) ideally, would contain a built-in mecha-
nism to assess therapeutic effects, such as a bioluminescent
reporter (see below). In reality, however, these criteria frequently
position themselves at odds with each other, making it difﬁcult to
completely satisfy them. For instance, models characterized by
rapidly forming tumors may not be sufﬁciently representative of
their human counterparts, especially with regard to issues of the
evolving microenvironment and the impact of additional stochastic
genetic events. GEMMs with short tumor latency may also contain
oncogenic drivers irrelevant to the human tumor in question and
express them so diffusely as to cause multifocal lesions, a situation
more reminiscent of cancer-predisposing syndromes than of con-
ventional unifocal tumorigenesis. Conversely, a single-minded
focus on precisely recapitulating all aspects of a given human
cancer for the purpose of drug testing has signiﬁcant drawbacks as
well. Such an approach not infrequently leads to complex models
characterized by sophisticated genetic engineering that while bio-
logically informative, may be challenging to effectively implement
in therapeutic trials.
Onarelatednote,recentadvancesingenomicshaveunderscored
the molecular heterogeneity exhibited by most brain tumors (2, 20,
22, 56, 67) and further emphasized that even individual diagnostic
categories are at best collections of genetically overlapping yet
distinct disorders that cannot be effectively represented by a single
GEMM.A more effective approach would seemingly be to employ
multiple GEMMs, each driven by relevant genetic abnormalities
that together encompass the full spectrum of molecular variability
inherent in these neoplasms. In this way, even relatively simple
models, driven by perturbations in single oncogenic pathways,
could be of considerable use, especially when testing drugs target-
ing those speciﬁc pathways. None of the GEMMs described in the
ensuing sections represents a perfect model for either glioma or
medulloblastoma with regard to preclinical trials. However, many
strikeaworkablebalancebetweenthecriteriadiscussedabove,and,
when taken together, embody a powerful resource for the testing of
promising treatment strategies.
MOUSE MODELS OF GLIOMA
Molecular pathology
Over the past two decades, investigations into the pathogenesis
of the various glioma subtypes have revealed central roles for a
deﬁned set of key biological pathways (Figure 1). The molecular
pathology of glioma has been reviewed extensively elsewhere (2,
20, 37, 51); this article will attempt to highlight important features
as they relate to recent successes in the murine modeling of
primary astrocytic and oligodendroglial tumors. In light of this, it
is worth mentioning that the genetic abnormality most frequently
associated with oligodendroglioma, namely loss of chromosome
1p and 19q (62), has not been effectively modeled in mice, partly
because the precise genes involved are not yet known.
The disruption of a set of tumor suppressor pathways with direct
effects on cell cycle control appears be crucial in the evolution of
glioma. The p53 gene is either mutated or deleted frequently in
astrocytic gliomas, particularly those that progress from low-grade
astrocytoma to GBM (so-called secondary GBM) (10, 45, 53).
Additionally, retinoblastoma (RB) is mutated in 10%–25% of high-
grade astrocytomas, and functionally silenced in another ~15%
through ampliﬁcation of its antagonist CDK4 (10, 30, 53). Similar
effects on the RB pathway are also frequently seen in anaplastic
oligodendroglioma (83). Lastly, the tumor suppressors INK4A and
ARF, positive regulators of RB and p53 respectively, are encoded
at the CDKN2A locus, which is deleted in approximately 50% of
high-grade astrocytomas and a signiﬁcant percentage of anaplastic
oligodendrogliomas as well (8, 10, 53, 77).
Receptor tyrosine kinases (RTKs) and their downstream signal-
ing pathways have been established as the primary oncogenic
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growth factor receptor locus (EGFR) occurs in ~40% of GBM, and
is considered to be the deﬁning genetic lesion of so-called primary
GBM (GBM that arises de novo rather than evolving from a lower
grade astrocytic lesion) (10, 53, 90). Furthermore, a constitutively
active deletion mutant of EGFR, EGFRvIII, is found in 20%–30%
of GBM (18). Platelet-derived growth factor (PDGF) and its recep-
tor(PDGFR)arefrequentlyupregulatedinbothlow-gradeastrocy-
toma and oligodendroglioma along with a deﬁned subset of GBM
(~13%), and the elevated expression of both suggests that
autocrine/paracrine loops between ligand and receptor enhance
their impact in glioma biology (10, 13, 53, 87).
The PI3K/AKT/mTOR pathway, operating downstream of
RTKs, exerts profound effects on cell growth, proliferation and
metabolism, and has been reported to be activated in up to~85% of
GBM (10, 53, 82). The phosphatase and tensin homolog (PTEN)
constitutes the primary negative regulator of this pathway, and
mutation or deletion of the PTEN gene, often by way of complete
loss of its locus on chromosome 10q, is found in a large percentage
of GBM (10, 38, 53). Furthermore, while discrete PTEN mutations
are much less frequent in high-grade oligodendroglial lesions,
loss of chromosome 10 remains common (8). The RAS/MAPK
pathway, also positioned downstream of RTKs, provides an addi-
tional mitogenic stimulus that is often dysregulated in astrocytic
glioma, despite a notable absence of activating RAS mutations in
mosthigh-gradevariants(10,24,53).Lossofthetumorsuppressor
NF1, a negative regulator of RAS signaling, may be central to this
process.Two recent large-scale sequencing projects have identiﬁed
frequent NF1 mutations in sporadic GBM (10, 53). Additionally,
germline NF1 mutations deﬁne the familial condition of
neuroﬁbromatosis 1, whose central nervous system (CNS) mani-
festations include increased incidence of diffuse atrocytoma, and,
most commonly, low-grade glioma of the optic nerve and chiasm
(OPG) (19).
Engineering and characteristics
Several GEMMs with considerable promise for preclinical testing
have been developed in recent years using combinations of the
glioma-associated genetic lesions highlighted in the preceding
paragraphs (Table 1). One such model for astrocytic glioma has
been established using combined Nf1 and p53 mutants (64).These
mice develop tumors spanning a range of histological grades
within a reasonable latency period (92% at 6 months), most result-
ing from loss of heterozygosity at the remaining wild-type Nf1
and p53 locus (the genes are located so close to each other in mice
that separate recombination events are rare). Furthermore, tumors
arising in older mice appear to be higher grade, implying that
this GEMM may have relevance in the modeling of more slowly
evolving astrocytic lesions like secondary GBM. Other non-CNS
cancers, most notably sarcoma, do arise in these mice at signiﬁcant
rates. Nevertheless, astrocytomas appear to be the most frequent
tumor type found in two of the four genetic backgrounds tested.
A similar model has been developed more recently by pairing
a p53 mutant allele with an Nf1 allele ﬂanked by loxP sites (a
so-called ﬂoxed allele). Crossing these mice with a transgenic line
expressing cre-recombinase under the glial ﬁbrillary acidic protein
(GFAP) promoter (GFAP-Cre) eliminates Nf1 in GFAP-expressing
astrocytes and glial precursors, effectively generating an Nf1/p53
double mutant in this cellular subpopulation (96). In this way,
Figure 1. Glioma-implicated signaling
pathways that have been employed in the
production of genetically engineered mouse
models. Oncogenes are shown in green, and
tumor suppressors are shown in red. Examples
of pharmaceutical agents are shown in
italicized blue with their targets indicated.
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brain. As would be anticipated, the incidence of non-CNS pathol-
ogy is dramatically reduced in this model.This beneﬁt, however, is
balanced by a somewhat longer disease-free latency (20–40
weeks),althoughcompletepenetranceremains.Thetumorsexhibit
a primarily astrocytic morphology, and frequently harbor high-
gradefeatures,suchasmicrovascularproliferationandpseudopali-
sading necrosis. Not surprisingly, the addition of a mutant Pten
allele to this model both decreases latency (to approximately
10–20 weeks) and increases tumor grade (41). As a side note,
GFAP-Cre-mediatedhomozygousdeletionofNf1intheabsenceof
p53 mutagenesis, while unable to produce parenchymal gliomas in
mice, generates OPGs with robust penetrance (3, 4, 97).
A separate set of GEMMs incorporating modulation of the Rb
pathway have been generated by transgenically expressing a trun-
catedSV40Tantigen(T121)undertheGFAPpromoter.Thismecha-
nism effectively inactivates the Rb pathway in mature astrocytes
and their precursors, and leads to ﬁbrillary astrocytomas in adult
mice (approximately 100% incidence at 300 days) (92). Further-
more, the presence of Pten null heterozygosity in this model sig-
niﬁcantly decreases disease-free latency and appears to enhance
tumor grade in terms of cellularity and mitotic activity (92, 93).
Although the dependence of this model on the expression of a viral
antigen is questionable from the standpoint of pure physiologic
relevance, it remains the only glioma GEMM produced to date
whose biology is centered on the Rb pathway.
Another large set of glioma GEMMs feature the overexpression
of relevant oncogenes—either RTKs or their downstream
effectors—coupled frequently with tumor suppressor loss.A series
of transgenic lines has been established, largely based on the
expression of a constitutively active Ras (V12Ras) under the GFAP
promoter (14, 15, 70, 84). The basic transgenic, expressing
only V12Ras, consistently develops astrocytic tumors, whose
histological grade, latency, and, at times, multifocality, appear to
depend on transgene dosage (14). High levels of V12Ras expres-
sion, for instance, yield multiple grade IV lesions per mouse
arising within the ﬁrst 2 weeks of life. Despite their strikingly rapid
onset, the induced tumors themselves appear to accumulate addi-
tional genetic and molecular alterations as they evolve from lower-
gradeprecursors(14,70).Thesechangesarereminiscentofglioma
pathogenesis and include decreased or absent expression of the
tumorsuppressorsPten,Ink4aandArf,andoverexpressionofEgfr,
the p53 antagonist Mdm2, and the cell cycle regulator, Cdk4. Such
ﬁndings perhaps bolster the physiologic relevance of this mouse
model despite its reliance on a mutated Ras protein not characteris-
tic of glioma biology. The additional expression of EGFRvIII in
this GEMM, either in a GFAP-driven transgene or by adenoviral-
mediated gene transfer, both decreases disease-free latency and
increases tumor grade while also inducing oligodendroglial histo-
logical features (15, 84). Finally, deletion of Pten, as in many other
models, decreases the age of tumor onset and potentiates the devel-
opment of high-grade lesions (84).
Another similar murine model of oligodendroglioma utilizes
transgenic expression of a transforming variant of EGFR, v-erbB,
under the S100ß promoter (85). The resulting tumors tend to be
low grade, with 60% incidence in 12 months. However, this model
doesnotrequireaconstitutivelyactiveRasvarianttoinduceglioma
formation. Furthermore, when v-erbB overexpression is paired
with Ink4a/Arf loss, tumor incidence increases to nearly 100% in
12 months, and high-grade features predominate. Intermediate
effectsareseenwheneitherInk4a/Arforp53nullheterozygotesare
used instead.
Many of the GEMMs described thus far achieve their effects
largely through the widespread expression of an oncogenic trans-
gene across the brain.Alternatively, tumor suppressors are mutated
in an equally extensive geographical distribution. While such
Table 1. Murine models of glioma shown with underlying genetics, mechanism of engineering, morphologic characteristics and incidence. Abbrevia-
tions: TG = transgenic; KO = knockout; Astro = astrocytic; Oligo = oligodendroglial; HG = high grade; LG = low grade.
Genetics Mechanism Morph/grade Incidence Reference
Nf1+/-; p53+/- Conventional KO Astro/variable 92% by 6 months (64)
Nf1+/-; p53+/- Conventional and conditional KO (GFAP-Cre) Astro/variable 100% by 5–10 months (96)
Nf1+/-; p53+/-; Pten-/- Conventional and conditional KO (GFAP-Cre) Astro/HG 100% by 5–8 months (41)
GFAPT121 TG Astro/LG 100% by 10–12 months (92)
GFAPT121; Pten-/- TG; conditional KO (MSCV-Cre) Astro/HG 100% by 6 months (93)
GFAP-V
12Ras TG Astro/HG 100% by 0.5–3 months (14)
GFAP-V
12Ras; EGFRvIII TG; adenovirus Oligo/HG 100% by 3 months (15)
GFAP-V
12Ras; Pten-/- TG; conventional KO Astro/HG 100% by 6 weeks (84)
S100-v-erbB TG Oligo/LG 60% by 12 months (85)
S100-v-erbB; Ink4a/Arf-/- TG; conventional KO Oligo/HG 100% by 12 months (85)
S100-v-erbB; p53+/- TG; conventional KO Oligo/variable 100% by 12 months (85)
PDGF-B MoMuLV Oligo/variable 40% by 10 months (79)
kRas; Akt RCAS Astro/variable 25% by 3 months (32)
kRas; Pten-/- RCAS; conditional KO (RCAS-Cre) Astro/variable 60% by 3 months (36)
kRas; Akt; Ink4a/Arf-/- RCAS; conventional KO Astro/variable 20%–50% by 3 months (78)
PDGF-B RCAS Oligo/variable 60%–100% by 3 months (12, 72)
PDGF-B; Ink4a/Arf-/-; Pten-/- RCAS; conventional KO; conditional KO (RCAS-Cre) Oligo/HG 60%–100% by 3 months (12)*
FIG-ROS; Ink4a/Arf/- Conditional TG (Adeno-Cre); conventional KO Astro/variable 100% by 3 months (11)
Nf1+/-
GFAPCKO Conditional KO (GFAP-Cre) in Nf1+/- mice Optic glioma 100% by 3 months (3, 4)
*Fomchenko and Holland, unpublished results.
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glioma, and, as we shall see, medulloblastoma models, their ﬁeld
cancerization effects are perhaps more akin to tumor-predisposing
conditions, such as Li Fraumeni syndrome and neuroﬁbromatosis
than sporadic brain tumorigenesis. The frequent occurrence of
multifocallesionsorevenfulminantwidespreadpathologyinsome
of these models perhaps emphasizes this point (14, 92).The use of
virusesformorelocalizedgenedeliveryhasemergedasanalterna-
tive mechanism for the production of brain tumors in GEMMs.
Thetightgeographicalrestrictionofcancer-forminggeneticevents
provided by viral transduction better resembles the analogous
human condition. Additionally, most viral systems allow for the
simultaneousdeliveryofmultiplegenesofinterest,eachinadiffer-
ent viral particle, in a variety of combinations, thus offering a fast
experimental readout by circumventing the often painstaking ger-
mline mutagenesis required to make multiple, distinct transgenic
or knockout lines.The drawbacks of this approach mainly concern
reduced tumor incidence in some models, and limitations on the
size of genes that can be effectively packaged within the viral
vectors themselves. Additionally, the actual delivery of the viral
reagent to the mouse brain, typically by injection, may represent a
technical challenge for some.
One of the initial workable models of brain cancer using viral
expression of a relevant oncogene utilized a murine retrovirus
(MoMuLV) to deliver the PDGF B-chain (PDGF-B) into the fore-
brains of newborn mouse pups (78). Approximately 40% of mice
developed tumors, whose histology spanned a wide range, resem-
bling either GBM or primitive neuroectodermal tumor (PNET) for
the most part, most likely reﬂecting heterogeneity in their cells of
origin. More recently, a series of GEMMs have been generated
employing an avian retrovirus, RCAS, for gene transfer while
genetically engineering its receptor, tv-a, into strains of mice under
the GFAP or nestin promoters (Gtv-a and Ntv-a, respectively) (32,
33) (Figure 2). In this way, the expression of exogenous transcript
is restricted geographically, as well as by cell type, to either astro-
cytes (Gtv-a) or glioneuronal progenitors (Ntv-a). The RCAS/tv-a
model yields astrocytic tumors (~25% incidence in 12 weeks) in
the N-tva background when constitutively active variants of both
kRas and Akt are used in combination as oncogenic drivers (34),
and deletion of Pten in these mice appears to phenocopy the effects
of RCAS-mediated Akt overexpression (36). Tumor incidence and
grade are increased when either Ntv-a or Gtv-a mice harboring
homozygous Ink4a/Arf deletion are used (79). For instance, Ntv-a/
Ink4a/Arf null mice injected with both RCAS-kRas and RCAS-Akt
demonstrate near 50% incidence in 12 weeks, with some tumors
exhibiting microvascular proliferation and necrosis. The subse-
quent development of RCAS-PDGF-B vectors has led to further
advances in the utility of this model system (12, 72). Ntv-a or Gtv-
a mice injected with RCAS-PDGF-B form oligodendroglial or
mixed oligoastrocytic tumors at high rates–up to 100% incidence
at 12 weeks depending on gene dosage (72). As in other models,
loss of tumor suppressors like Ink4a/Arf and Pten dramatically
decreasesdisease-freelatencyandincreasetheappearanceofhigh-
grade features (12).

Figure 2. Examples of murine brain tumor models incorporating RCAS/
tv-a technology. A. High-grade glioma driven by RCAS-PDGF and RCAS-
Cre in an Ntv-a; Ink4a/Arf-/-; ﬂoxed PTEN background. Black arrows
indicate pseudopalisading necrosis, and white arrows highlight foci of
microvascular proliferation. B. High-grade glioma driven by RCAS-kRAS
and RCAS-Akt in an Ntv-a; Ink4a/Arf-/- background. Black arrows indi-
cate necrosis. C. Medulloblastoma driven by RCAS-SHH in an Ntv-a
background. All micrographs were taken at 20¥ magniﬁcation.
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GEMM driven by a constitutively active fusion RTK (FIG-ROS).
While the presence of FIG-ROS in glioma has been seen in only
two tumor-derived cell lines to date, overexpression of the native
ROSkinasedoesoccursomewhatmorefrequentlyinactualtumors
(~30% of cases) and activates similar signaling cascades to those
directed by EGFR and PDGFR (91). The model features a ﬂoxed
stop codon immediately preceding the FIG-ROS transgene that
is then removed by a Cre-expressing adenovirus allowing
transcription (11). When this approach is applied in mice lacking
Ink4a/Arf, astrocytic tumors form, exhibiting a range of histologi-
cal grades, most within a reasonable temporal window (~80% inci-
dence at 15 weeks). Furthermore, activation of relevant signaling
networks, such as the Akt pathway, is present, perhaps pointing to a
more generalized applicability for this model to studies like pre-
clinical testing, despite its reliance on a genetic lesion not associ-
ated with the vast majority of gliomas.
MOUSE MODELS OF
MEDULLOBLASTOMA
Molecular pathology
Multiple molecular pathways and genetic abnormalities have been
implicated in the pathogenesis of PNET and its most common
variant, medulloblastoma. As for glioma, this review will focus
primarily on the molecular mechanisms that have been employed
most frequently in the construction of medulloblastoma GEMMs
showing promise for preclinical studies. This will unfortunately
exclude any discussion of wingless and ERBB signaling, both of
which appear to play a central role in medulloblastoma, as well as
themostfrequentgeneticlesionassociatedwiththetumor,isochro-
mosome 17q. For more extensive coverage of these subjects,
readers are encouraged to look elsewhere (21, 67).
Over the last decade and a half, numerous investigations have
implicated sonic hedgehog (SHH) signaling in medulloblastoma
pathogenesis (21, 67), and modulation of the SHH pathway has led
to the vast majority of the medulloblastoma GEMMs currently
available. A schematic of SHH signaling is shown in Figure 3.
Brieﬂy, the binding of SHH to its receptor patched (PTCH)
removes the latter’s inhibitory effects on the downstream effector
smoothened(SMO).SMOtheninitiatessignalingeventsleadingto
the release of the GLI family of transcription factors from inhibi-
tory protein complexes that include suppressor of fused (SUFU).
This process results in the eventual transcription of GLI target
genes and the consequent physiologic effects, including cell prolif-
eration in the right cellular context (39). The SHH pathway was
ﬁrst implicated in medulloblastoma when germline mutations in
the PTCH1 gene were found to be the cause of Gorlin’s syndrome,
a congenital condition characterized by increased incidence of
basal-cell carcinoma, medulloblastoma and rhabdomyosarcoma
(25). Since then, mutations in multiple components of the SHH
signaling cascade have been identiﬁed in sporadic medulloblas-
toma, speciﬁcally inactivating mutations in PTCH1 and SUFU and
activating mutations in SMO, together accounting for 15% of all
cases (57, 59, 63, 75). Interestingly, medulloblastomas character-
izedbymutationsintheSHHpathwaytendtoexhibitdesmoplastic
morphology.
Additional oncogenes and tumor suppressors have been linked
to medulloblastoma pathogenesis. Germline mutations in p53 lead
to Li-Fraumeni syndrome, which is characterized by increased
incidence of a number of different tumor types, including medullo-
blastoma (46). Furthermore, p53 mutations have also been identi-
ﬁed in sporadic variants of this tumor with poor clinical outcome
(76).The oncogenes N-MYC and C-MYC are notably ampliﬁed in a
subset of medulloblastoma that tends to demonstrate anaplastic
features and aggressive biological behavior (1, 76). Finally,
insulin-like growth factor-2 (IGF2) overexpression has been found
in a portion of sporadic medulloblastoma, mainly of the desmo-
plastic subtype (58).
Engineering and characteristics
As stated above, the plurality of medulloblastoma GEMMs gener-
ated to date derive from exogenous manipulation of the Shh
pathway (Table 2). Mice hemizygous for Ptch (Ptch+/-) develop
medulloblastoma at a relatively modest rate of 14%–19% by 10
months (23, 88, 98). A signiﬁcant number of other tumors, most
notably soft tissue sarcomas, also form in this GEMM (44, 88).
Interestingly, the remaining Ptch allele in these mice appears to be
functional in a majority of generated medulloblastomas, suggest-
ing that mere haploinsufﬁciency increases Shh signaling enough
to mediate tumorigenesis (54, 88, 98). Irradiating these mice
during the early postnatal period dramatically increases tumor
incidence—ashighas100%by10months—mostlikelyduetoloss
of heterozygosity at the remaining Ptch locus, coupled with muta-
tions in other relevant genes like p53 (54, 55). Medulloblastoma
frequency in the Ptch+/- model has also been improved through
the use of more discrete genetic modiﬁcations. Complete loss of
Figure 3. SHH signaling pathway components that have been
employed in the production of genetically engineered mouse models.
Oncogenes are shown in green, and tumor suppressors are shown
in red. Examples of pharmaceutical agents are shown in italicized blue
with their targets indicated.
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10–12 weeks (89), and functional deletion of the Ptch homologue
Ptch2 has similar, if more modest, effects (44). A related murine
model employs hemizygous loss of Sufu in a p53 null background
(Sufu+/-/p53-/-), yielding medulloblastomas in 58% of mice over
the course of 10 months (42). Lastly, a particularly robust GEMM
has been generated using a constitutively active Smo allele
(SmoA1) under the control of the granule neuron precursor-
speciﬁc promoter ND2 (26, 28). Ninety four percent of homozy-
gous SmoA1/SmoA1 mice develop medulloblastoma by 2 months
of age, and these tumors frequently exhibit leptomeningeal spread,
a common feature of the human disease (28). Furthermore, the
localization of transgene expression to granule neuron precursors
eliminates the occurrence of non-CNS pathology, perhaps simpli-
fying the implementation of this model in preclinical studies.
Indeed, a similar GEMM employing an activated Smo under a
ubiquitously expressed inducible driver leads to widespread neo-
plastic lesions, including, but not limited to, medulloblastoma in
40% of cases (47).
Two other recently developed model systems also minimize the
incidence of non-CNS tumors by limiting causal genetic events to
particularcelltypes.OneseriesutilizesconditionalPtchknockouts
pairedwithpromoter-restrictedCredrivers(95).Inthisway,lossof
Ptchislocalizedtoeithergranuleneuronprecursorsormoreprimi-
tive cerebellar neural stem cells by using Math1-Cre or GFAP-Cre
transgenes, respectively.The other group of GEMMs uses a similar
strategy, employing Math1 and GFAP-driven Cre to instead direct
the expression of an activated Smo allele. However, they also in-
corporate two additional drivers, Olig2-Cre and Tlx3-Cre, whose
spatial expression pattern within the murine cerebellum differs
from those of GFAP-Cre and Math1-Cre (69). In all cases,
medulloblastomas with similar, if not identical, histological fea-
tures,developatrobustlevels—ashighas100%by4weeksofage.
The variability of tumor incidence with regard to individual
Cre-drivers does differ somewhat between the two model
systems, most likely caused by the contrasting causative
oncogenic events (ie, Ptch loss vs. forced Smo overexpression).
Interestingly, the spatial distribution of the generated medulloblas-
tomas corresponds to that of their transgenic driver, and, presum-
ably, their cell of origin. This ﬁnding underscores the potential
utility of these models in preclinical testing, despite their more
complex and cumbersome genetics. The therapeutic targeting of
different cell types within a heterogeneous tumor mass has become
a major focus of translational cancer biology (see below). The
ability to generate of an array of medulloblastomas from differing
cells of origin provides and inviting substrate for investigations on
this topic.
Medulloblastoma models have also been generated by retroviral
gene transfer in a similar fashion to that used for the production
glioma GEMMs. One group has used the RCAS/tv-a system to
create a series of GEMMs driven by Shh expression (7, 49, 60, 61).
Cerebellar application of RCAS-Shh alone to Ntv-a mice yields
medulloblastomas at a rate of 9%–34% with a median latency of
roughly 6–7 weeks (Figure 2). Co-injection of any one of a number
of additional oncogenes, such as c-myc, Akt, IGF2, and n-myc
enhances the strength of the phenotype, the greatest effects occur-
ring with a combination of Shh and a stabilized n-myc mutant.This
latter tumor type also exhibits an increased mitotic index reminis-
cent of the anaplasia associated with myc ampliﬁcation in human
medulloblastoma (7). RCAS-mediated expression of Shh, together
with the antiapoptotic factor Bcl-2, also appears to increase the
frequency of tumor formation (49). Decreased levels of apoptosis
in this model have been conﬁrmed.
Only a handful of medulloblastoma GEMMs not driven by Shh
signaling have been developed to date (Table 2). Two such models
utilizehomozygous,forthemostpart,lossofp53asthefoundation
oftheirgeneticdesign.InoneGEMM,thisstrategyiscoupledwith
partial or complete loss of Rb in cerebellar granule neurons by way
Table 2. Murine models of medulloblastoma shown with underlying genetics, mechanism of engineering and incidence. Abbreviations:
TG = transgenic, KO = knockout.
Genetics Mechanism Incidence Reference
Ptch+/- Conventional KO 14%–19% by 10 months (23, 44, 98)
Ptch+/- Conventional KO; irradiation 100% by 10 months (54, 55)
Ptch+/-; p53-/- Conventional KO 100% by 2–3 months (89)
Ptch+/-; Ptch2/- Conventional KO 17% by 10 months (44)
Ptch+/- Conditional KO (GFAP-Cre, Math1-Cre) 100% by 1–3 months (95)
ND2-SmoA1 TG 94% by 2 months (26, 28)
SmoM2 Conditional TG (GFAP-Cre, Math1-Cre, Olig2-Cre, Tlx-Cre) 100% by 2–4 months* (69)
Sufu+/-; p53-/- Conventional KO 58% by 10 months (42)
Shh RCAS 9%–34% by 3 months (7, 49, 60, 61)
Shh; c-myc/Akt/IGF2 RCAS 23%–48% by 3 months (60, 61)
Shh; n-myc RCAS 78% by 3 months (7)
Shh; Bcl-2 RCAS 78% by 3 months (49)
Rb/-; p53-/- Conditional KO (GFAP-Cre) 25%–100% by 2–7 months (48)
Ink4c/-; p53/- Conventional and conditional KO (Nestin-Cre); irradiation 20%–100% by 5 months (81)
Ptch+/-; Ink4c/- Conventional KO 40%–50% by 9 months (81)
Lig4-/-; p53-/- Conventional KO 100% by 2 months (43)
Brca2-/-; p53/- Conventional and conditional KO (Nestin-Cre) 72%–83% by 4–8 months (17)
Xrcc4-/-; p53-/- Conventional and conditional KO (Nestin-Cre) 100% by 6 months (94)
*Estimated from reported average latency.
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results in medulloblastoma formation in a majority of mice follow-
ing a relatively long latency period—76 to 196 days—with the
precise rate of incidence depending somewhat on the level of
remaining Rb activity. In the other model system, medulloblasto-
mashavebeensuccessfullygeneratedbyirradiating5-dayoldmice
harboring mutations in both p53 and the tumor suppressor Ink4c,
with an incidence between 20% and 100%, depending on the
zygosity of both genes (81). The physiologic relevance of these
models might provide some cause for question. While both germ-
line and sporadic p53 mutations have been associated with human
medulloblastoma, a central role for the gene in the pathogenesis of
the tumor is less certain; and defects in the Rb pathway are rarely
seen. One might even expect gliomas to form in the ﬁrst of these
model systems, given its GFAP-dependent distribution of genetic
lesions that seem more appropriate to that tumor type. However,
none are reported (48). Regarding Ink4c, the same study that
describes the GEMM reports methylation at the gene locus in 4 of
23examinedcasesofhumanmedulloblastoma.Additionally,Ink4c
loss is applied to the standard Ptch+/- GEMM, leading to a modest
enhancement of phenotype (~45% incidence) (81).
Finally, another group of GEMMs has employed generalized
genomic instability to effectively produce medulloblastoma in
mice. In these models, p53 deﬁciency is typically paired with loss
ofcrucialDNArepairenzymes,suchasLig4,Xrcc4andBrca2(17,
31,43,94).Asaninterestingsidenote,mutationsinthislattergene
have been associated with Fanconi’s anemia, a systemic condition
characterized by, among other things, a predisposition to develop
medulloblastoma (52). The most effective of these models restrict
their genetic defects to neuroglial progenitor cells using ﬂoxed
alleles and nestin-Cre drivers. This results in a relatively high rate
of medulloblastoma formation, with most mice succumbing within
120–180 days. Furthermore, genetic analysis of the generated
tumors reveals mutations, as well as ampliﬁcations at genetic loci
commonly affected in medulloblastoma, such as Ptch, c-myc,
n-myc and p53 (17, 94). Such ﬁndings support the use of these
modelsystemsinpreclinicaltrialsbyhighlightingtheirphysiologi-
cal relevance.
CONSIDERATIONS FOR PRECLINICAL
STUDIES USING BRAIN TUMOR GEMMS
Pathway-targeted therapies
While none of the glioma or medulloblastoma GEMMs described
in the preceding sections completely phenocopies their respective
human conditions, their combined utility in the preclinical testing
of therapeutic regimens remains obvious. Over the past two
decades, rational drug design has led to numerous small molecule
inhibitors targeting many of the oncogenic pathways involved in
brain tumor pathogenesis (examples given in Figures 1 and 3), the
same pathways modulated, either singly or in combination, in the
design of glioma and medulloblastoma GEMMs. Consequently,
these models constitute ideal in vivo systems in which to study the
effects of particular drugs on their molecular targets and the conse-
quences for tumorigenesis. Additionally, the systemic toxicity of
individualcompoundscanbegauged,andstrategiestofollowclini-
calcourseformulated.Despitethesepossibilities,onlyahandfulof
such studies have been performed to date.
The effects of PTK787, a PDGFR and vascular-endothelial
growth factor receptor (VEGFR) inhibitor, have been tested in
the aforementioned RCAS-PDGF-mediated oligodendroglioma
model (72, 80). A 70-day course of PTK787, given at 100 mg/kg/
day, leads to lower-grade histology in treated tumors characterized
by markedly decreased mitotic activity, although tumor vascularity
appears unchanged (72).This GEMM has also been used to assess
the in vivo impact of perifosine, an oral inhibitor of the AKT and
RAS/MAPK pathways, both of which are known to be activated by
the enhanced RTK signaling common in glioma (50). Mice treated
with a combination of 100 mg/kg temozolomide and 30 mg/kg
perifosine for 3–5 days exhibit tumors with a signiﬁcantly
decreased proliferation index. Furthermore, the combined effects
of perifosine and temozolomide are greater than for either drug
alone.This study demonstrates (i) how GEMMs can be used to test
drugs targeting pathways that are not directly altered in the genetic
design of the model (in this case the crucial signaling networks are
downstream of the exogenous oncogenic stimulus); and (ii) the
utility of GEMMs in the analysis of multiple drugs or therapeutic
modalities in combination.
Similar studies have been performed on glioma GEMMs exhib-
iting more astrocytic histology. The previously described RCAS-
kRas/RCAS-Akt-driven astrocytoma model has been used to
evaluate CCI-779, an inhibitor of mTOR (36). Treated tumors
harbor large areas of necrosis and apoptosis, and, interestingly,
surrounding viable tissue exhibits a more oligodendroglial mor-
phology.These ﬁndings not only highlight the therapeutic potential
of CCI-779 and its related compounds, but also underscore the
importance of mTOR signaling both for tumor survival and the
maintenance of astrocytic character.This study also yields relevant
dosing information, with the effective daily regimen of 40 mg/kg
far exceeding the 0.1 mg/kg found to be active in xenografts, illus-
trating the importance of an intact blood–brain barrier for
the proper in vivo analysis of potential brain cancer therapies. The
impact of Ras pathway inhibition has also been assessed in the
homozygous Nf1-deleted OPG model mentioned earlier. In these
mice, the mTOR inhibitor rapamycin appears to decrease both
tumorcellproliferationandtumorsizeinadose-dependentfashion
(29). The study incorporates temozolomide treatment as well,
althoughnoenhancedeffectisseenwhencombiningthetwodrugs.
Medulloblastoma models have also been used effectively in the
preclinical testing of targeted therapeutics. The recent ﬁnding that
SHH pathway activity is downregulated in medulloblastoma cells
oncetheyareplacedintissueculturefurtheremphasizestheimpor-
tance of in vivo systems in these types of investigations (6, 68).
Ptch+/-/p53-/- mice treated with HhAntag, an inhibitor of SHH
signaling, exhibit complete tumor eradication at a dose of 100 mg/
kg/day (66). Additionally, mice maintained on HhAntag remain
medulloblastoma-free for as many as 147 days. These dramatic
effects, however, have been somewhat tempered by subsequent
studies identifying bone defects in young mice after even transient
exposure to this drug (40).
Pharmacology by way of genetic engineering
GEMMs need not be treated directly with drugs to successfully
inform subsequent clinical trials. Indeed, the potential effects of
targeting vital oncogenic pathways in brain tumors can be modeled
simply by manipulating the underlying genetics of relevant
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oncogenic stimulus can be assessed, even in the absence of a test
compound. This approach has been applied for glioma using an
RCAS-kRas/RCAS-Akt-driven astrocytoma model, in which kRas
expression is dependent on the administration of doxycycline (35).
Addition of doxycycline after tumor formation leads to complete
loss of kRas expression and dramatic tumor regression and subse-
quent withdrawal of tetracycline restores kRas expression, result-
ing in tumor recurrence within 3 weeks. These ﬁndings indicate a
requirement for Ras signaling in the maintenance astrocytoma,
bolstering the case for inhibition of this pathway in antiglioma
therapies.
Radiotherapy
Ionizing radiation constitutes a major therapeutic modality in the
treatment of both glioma and medulloblastoma, although much of
thebiologyunderlyingitseffectsandthemechanismsoftumorcell
resistanceremainunclear.ThehighﬁdelitytowhichGEMMsreca-
pitulate both the genetics and the characteristic tumor–stroma
interactions of brain cancer would seem to make them ideal
systems for the reﬁnement of more effective radiotherapy regi-
mens, especially in combination with synergistic drugs. Never-
theless, this avenue of translational research remains largely
unexplored. An investigation into the irradiation of medulloblas-
toma using the RCAS-Shh-based model system has recently been
reported (27). Radiotherapy is found to induce widespread, p53-
mediated, apoptotic cell death in the tumor bulk, which is largely
absent in a p53 null background. Furthermore, a subset of radiore-
sistant stem-like tumor cells characterized by their perivascular
distribution (9) appear to activate PI3K/Akt/mTOR signaling
following irradiation, undergo brief cell-cycle arrest and then
gradually begin dividing again, presumably leading to disease
recurrence. Intriguingly, combined radiation and treatment with of
the AKT pathway inhibitor perifosine appears to signiﬁcantly
decrease survival in this cellular subpopulation.These ﬁndings not
only provide in vivo insight into the biology of irradiated tumors,
but also uncover a promising therapeutic strategy for radiosensiti-
zation in medulloblastoma. On a different level, this study also
indicates that p53 loss matters greatly with regard to radiotherapy,
and that p53-/-tumors will not behave in the same fashion as the
majority of human medulloblastomas that are p53-intact.
Cancer stem cell biology
ThecellularheterogeneityexhibitedbysomebraintumorGEMMs,
as highlighted in the preceding paragraph, offers a distinct advan-
tage when studying the impact of test therapies on important sub-
populations of cells like CSCs. As we have seen, the causative
genetic or molecular events in GEMMs are frequently targeted to
progenitor cells or other similar groups with stem-like character
(Tables 1 and 2). Furthermore, tumors in some models even appear
to localize at their earliest stages to brain regions rich in multipo-
tent stem cells (96). The means to identify CSCs within tumor
masses are also improving steadily, as evidenced by identiﬁcation
of the brain CSC marker CD133 (73). Recently, one group has
taken advantage of the singular ability of stem cells to efﬂux drugs,
as well as the ﬂuorescent Hoechst dye, to isolate CSCs from a
PDGF-driven glioma model by ﬂuorescent-activated cell sorting
(Bleau, AM and Holland, EC, unpub. obs.). By obtaining a rela-
tively pure population of stem-like cells, they are able to demon-
strate the importance of the Akt pathway in the maintenance of
CSC characteristics, in particular the resistance to alkylating
agents like temozolomide. Additional studies like this one should
furtherclarifymechanismsfortheeffectivetargetingofthiscrucial
class of tumor cells.
In vivo imaging
Improvements in imaging technology have further enhanced the
promise of preclinical testing in brain tumor GEMMs. Magnetic
resonance imaging (MRI) has already been successfully employed
in the analysis of drug effects on brain tumor models of both
oligodendroglial and astrocytic lineage (36, 72). In these studies,
high-grade lesions were identiﬁed by MRI and followed serially
duringtreatmentwithobserveddecreasesincontrastenhancement.
Drug efﬁcacy was then conﬁrmed histologically. The more recent
development of genetically engineered bioluminescent reporter
mice has brought with it the ability to query distinct molecular
pathways and signaling networks and assess their response to
therapeutic intervention. One such system utilizes an E2F1-
luciferase transgene, expressed primarily in dividing cells, that
mediates the release of light in the presence of the bioluminescent
compound luciferin. Consequently, groups of rapidly multiplying
cells in these mice, such as tumors, release sufﬁcient light so as to
be detectable by a sensitive luminometer, even when transmitted
through skin, soft tissue and bone. This strategy, in the context of
a PDGF-driven glioma GEMM, has been used to successfully
monitor the effects of pharmacologic PDGFR inhibition on tumor
growth (80). Other reporter mice have also been generated, includ-
ing a GLI-response luciferase transgenic that demonstrates Shh
signaling (6). The creation of these additional bioluminescent
strains for the analysis of molecular pathways implicated in brain
tumor biology should greatly streamline the process of testing tar-
geted therapies in murine model systems.
CONCLUDING REMARKS
As advances in cancer biology continue to reveal the molecular
mechanismsunderlyingbraintumorpathogenesis,thesuccesswith
which such discoveries are translated into effective therapies has
cometodependontheabilityofthescientiﬁccommunitytorapidly
screen potential therapies in appropriate in vivo systems. Well-
designed drug tests in murine models of brain cancer should not
only serve to rapidly isolate promising therapeutic strategies, but
should also better inform subsequent trials in human subjects, and,
in doing so, both lower their cost and increase their efﬁcacy. This
review has attempted to brieﬂy overview the currently available
glioma and medulloblastoma GEMMs, and their potential for
applications in preclinical testing. In many ways, these murine
model systems remain a largely untapped resource (65), as evi-
denced by the relatively small number of studies successfully
employingGEMMsinpreclinicaltrialstodate.Moreextensiveuse
of brain tumor GEMMs in this kind of translational research will
hopefully underscore their utility as effective disease models and
facilitate the development of the next generation of molecularly
targeted therapeutics.
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